Breast can­cer ap­proval in tow, As­traZeneca, Dai­ichi armed an­ti­body scores in key gas­tric can­cer study

As­traZeneca kicked off Mon­day with a flur­ry of good news. Apart from un­veil­ing pos­i­tive re­sults on its stroke tri­al test­ing its clot-fight­er Bril­in­ta, and wel­com­ing its ex­per­i­men­tal IL-23 in­hibitor brazikum­ab back from Al­ler­gan — the British drug­mak­er al­so dis­closed some up­beat gas­tric can­cer da­ta on its HER2-pos­i­tive on­col­o­gy ther­a­py it is col­lab­o­rat­ing on with Dai­ichi Sankyo.

Buoyed by the per­for­mance of its on­col­o­gy drugs, last March As­traZeneca chief Pas­cal So­ri­ot bet big to part­ner with Dai­ichi on the can­cer drug, with $1.35 bil­lion up­front in a deal worth up to rough­ly $7 bil­lion. Rough­ly 8 months lat­er, as 2019 drew to a close, the FDA swift­ly ap­proved the drug — trastuzum­ab derux­te­can — for use in breast can­cer, months ahead of the ex­pect­ed de­ci­sion date.

Trastuzum­ab derux­te­can, brand­ed as En­her­tu, is an an­ti­body-drug con­ju­gate (ADC) — ther­a­peu­tics in which a can­cer-killing tox­in is at­tached to a spe­cif­ic an­ti­body us­ing a biodegrad­able link­er — for can­cers that ex­press HER2, a pro­tein as­so­ci­at­ed with ag­gres­sive dis­ease that of­ten re­sides on cer­tain breast can­cer cells. Rough­ly one in five gas­tric can­cers are HER2 pos­i­tive, As­traZeneca said.

The piv­otal mid-stage tri­al, DES­TINY-Gas­tric01, test­ed En­her­tu against chemother­a­py in 189 pa­tients from Japan and South Ko­rea with HER2-ex­press­ing ad­vanced gas­tric can­cer or gas­troe­sophageal junc­tion ade­no­car­ci­no­ma, whose dis­ease pro­gressed de­spite two or more pri­or treat­ment reg­i­mens in­clud­ing flu­o­ropy­rim­i­dine and plat­inum chemother­a­py and trastuzum­ab.

The tri­al met the main goal of in­duc­ing sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in ob­jec­tive re­sponse rate (ORR), as well as the key sec­ondary end­point of over­all sur­vival. De­tailed da­ta are still to come.

Whilst a small­er in­di­ca­tion than HER2+ metasta­t­ic breast can­cer, this still rep­re­sents a sig­nif­i­cant op­por­tu­ni­ty with an es­ti­mat­ed rough­ly 10,000 HER2+ metasta­t­ic gas­tric can­cer pa­tients in the US, top 5 EU mar­kets and Japan, Jef­feries’ an­a­lyst Pe­ter Welford wrote in a note.

Welford’s $2.05 bil­lion in risk-ad­just­ed glob­al peak sales for En­her­tu is pre­dom­i­nant­ly based on the ther­a­py’s oth­er in­di­ca­tions, par­tic­u­lar­ly metasta­t­ic breast can­cer, he said, adding that just $330 mil­lion of that ac­counts for gas­tric can­cer.

Most pa­tients di­ag­nosed with gas­tric can­cer present with ad­vanced, in­cur­able dis­ease — trastuzum­ab in com­bi­na­tion with chemother­a­py is typ­i­cal­ly the first line of de­fense in pa­tients with metasta­t­ic HER2-pos­i­tive gas­tric and gas­troe­sophageal can­cer. Once the dis­ease no longer re­sponds to trastuzum­ab — pa­tients have lim­it­ed op­tions.

Dai­ichi, which ex­pects the drug to reap peak sales up to $4.5 bil­lion across dif­fer­ent in­di­ca­tions, is on track to take for­ward the drug’s ap­pli­ca­tion ini­tial­ly in Japan where gas­tric can­cer is high­ly preva­lent. En­her­tu is an HER2-tar­get­ed ADC with a topoi­so­merase I in­hibitor pay­load — a chemother­a­peu­tic agent de­signed to in­ter­rupt DNA repli­ca­tion in can­cer cells, and is al­so be­ing test­ed in oth­er can­cers.

In 2015, Roche’s Kady­cla, known chem­i­cal­ly as trastuzum­ab em­tan­sine, failed to elic­it any ben­e­fit in pa­tients pre­vi­ous­ly treat­ed for HER2-pos­i­tive ad­vanced gas­tric can­cer. Last April, Mer­ck’s star PD-1 ther­a­py Keytru­da failed to po­si­tion it­self in the front­line gas­tric can­cer set­ting, al­though it has al­ready se­cured ap­proval as a third-line treat­ment.

The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers

“Each generation needs a new music,” Francis Crick wrote in 1988, reflecting back on his landmark discovery. Crick was 35, then, in 1953, when he began working with a 23-year-old named James Watson, and 37 when the pair unveiled the double helix. Rosalind Franklin, whose diffraction work undergirded their metal model, was 32.

The model would become the score for a new era in biology, one devoted to cracking the basic structures turning inside life. Subsequent years would bring new conductors and new rhythms: Robert Swanson, 29 when he convinced a 39-year-old Herb Boyer to build a company off his work and call it Genentech; Phillip Sharp, 29 when he discovered RNA splicing and 34 when he co-founded Biogen; Frances Arnold, 36 when she pioneered directed evolution; Feng Zhang, 31 when he published his CRISPR paper.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,700+ biopharma pros reading Endpoints daily — and it's free.

Chart-top­ping ven­ture cash? Strong deal flow? In the month Covid-19 ripped around the globe? Yup

It turns out that even sending everyone from the CEO to rank-and-file staffers home to work in the middle of a Category 5 pandemic wasn’t enough to put a crimp in the flow of venture cash into biopharma. And even dealmaking held its own against the howling winds of misfortune — largely because a group of savvy players was quick to adjust to the new reality.

Our deal expert Chris Dokomajilar ran the numbers for us on a month-to-month basis and found that not only was venture money flowing during the panicky month of March, but it was also hitting home in record sums compared to the last 26 months of deal flow.

Say what?

As you can see in the top chart below, Dokomajilar outlined how the industry racked up $2.41 billion in total for March, just barely ahead of one other topper during the heady days of August 2018.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

FDA Commissioner Stephen Hahn and President Donald Trump at a press briefing on March 19, 2020. (AP Images)

Biotech ex­ecs warn that the FDA is fum­bling their re­sponse to the Covid-19 open-door promise, de­lay­ing progress

A few days ago the FDA touted a procedure for Covid-19 meds that committed the agency to immediate action for developers, formalizing a high-speed response that’s been promised for weeks.

Bioregnum Opinion Column by John Carroll

Decisions that once required months would be measured in hours under the Coronavirus Treatment Acceleration Program. “In many cases” trial protocols could be hammered out in less than a single day. If you had a potential solution to the crisis, the appropriate staffer would be in touch “to get studies underway quickly.”

It would be the ultimate high-speed regulatory pathway from Phase I to approval. Red tape was banished.

But it’s clear that for some — and quite likely many — biopharma execs, the actual agency response has not measured up to the promise. Beyond the front ranks of advanced companies in the field, like Gilead, or for drugs endorsed by President Trump, it may not even come close.

“The first response is this form letter everyone gets,” says one biotech CEO who’s reached out to the FDA on Covid-19. And when you try to cut through that, the ball gets dropped as it is passed from top officials to the frontline staff actually charged with getting things done.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

GSK's Hal Bar­ron buys a $250M stake in George Scan­gos' Vir and makes a bee­line to the clin­ic with Covid-19 an­ti­bod­ies

GlaxoSmithKline is diving straight into the swirling waters of Covid-19 R&D work, and investing $250 million to grab a chunk of equity in one of the emerging stars in infectious disease research to make it official.

GSK put out word this morning that it is partnering with Vir Biotechnology $VIR, the infectious disease startup founded in the Bay Area by former Biogen CEO George Scangos. They’re planning a leap into Phase II studies for 2 preclinical antibody candidates — VIR-7831 and VIR-7832 — that have been engineered to target the SARS-CoV-2 spike protein.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,700+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: A small, ob­scure biotech just won big with their IPO. In this mar­ket. Are you kid­ding me?

How could a small, largely unknown biotech that emerged from stealth mode just months ago with early-stage cancer programs jump onto Wall Street in the middle of a Category 6 financial hurricane and sail through with a $165 million IPO?

And what does that mean for the rest of the industry waiting to see just how much damage global lockdowns will wreak on clinical development?

The biotech is a company called Zentalis. The crew there nabbed an $85 million crossover round late last year — notably waiting 5 years before waving the numbers around to attract attention, according to my read of a FierceBiotech story. Perceptive joined in, but the syndicate was not in general the kind of marquee affair that gets tongues wagging.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Ready to de­clare a de­fin­i­tive come­back in two months, Im­munomedics stops PhI­II ear­ly, re­cruits new CEO

More than a year ago, hit by a surprise complete response letter from the FDA, Immunomedics bid its then-CEO, Michael Pehl, adieu and began a 15-month quest to resolve the manufacturing issues cited in the CRL and seek a new leader — all the while moving forward with a Phase III study on its lead drug for metastatic triple-negative breast cancer.

Today the biotech said their stars are finally aligning. Not only is Novartis Oncology vet Harout Semerjian coming on board as CEO to steer what they believe will be a smooth sail to a new PDUFA date in June, Immunomedics has also been informed that their late-stage trial can be stopped early due to “compelling evidence of efficacy.”

An­oth­er day, an­oth­er boat­load for biotech. Deer­field adds $840M to rush of ven­ture dol­lars

The biotech dollars just keep rolling in.

Even as the world economy faces an economic contraction unprecedented in nature, biotech venture capital firms are announcing huge new investment pots. The latest? Deerfield Management Co.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,700+ biopharma pros reading Endpoints daily — and it's free.

Small mol­e­cules, bi­o­log­ics and now gene ther­a­pies: Ger­many's Evotec adds an­oth­er feath­er to its R&D cap

German drug discovery company Evotec — which has a thriving rolodex of biopharma partners such as Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Pfizer, Sanofi, and Takeda — is now venturing into gene therapies.

The company swallowed Seattle-based Just Biotherapeutics, a company focused on reducing the cost of manufacturing protein therapies last year. It is now setting up a dedicated R&D site for gene therapies in Austria, in an effort to achieve a “modality-agnostic” repertoire — small molecules, biologics and now gene therapies.

A pair of PhI­II fail­ures spells last rites for Men­lo’s once-promis­ing Mer­ck drug

Four months after an intercontinental merger, Menlo Therapeutics is counting yet another pair of trial failures — ones with significant consequences for the companies, their shareholders and the drug.

In two pivotal Phase III trials, Menlo’s lead drug serlopitant failed to treat pruritus associated with prurigo nodularis — basically itchiness from a particular skin disease that causes red lesions on a person’s arms or legs. Serlopitant has long been the company’s only drug and as recently as 2018, it looked promising enough to support a stock price of $37. In April of that year, a Phase II failure demolished the stock price overnight: $35 to $9. Other subsequent stumbles trickled the ticker down to just above $2.